View the Mueller Europe entry on BPindex
Visit the Mueller Europe website
Mueller Europe is already recognised as the largest manufacturer of copper tube and pipe in the UK. In January 2026, the Mueller Europe Healthcare & Life Sciences division was established to commercialise and deliver solutions into the NHS to aid in the fight against the transmission of deadly multidrug-resistant gram-negative bacteria. Mueller Europe are now proud suppliers to the NHS and broader healthcare markets through the Healthcare division.
Sink and drain infrastructure is widely recognised as a direct transmission pathway for these gram-negative bacteria to ascend back into clinically vulnerable areas. It is acknowledged that “splash-back” from plug outlets is a direct and specific mechanism by which pathogens move from drains / U-bends back into the clinical environment, onto hands, surfaces and then patients. It can happen every time a tap runs and for Estates and infection prevention teams, already stretched thin, that is a risk sitting in plain sight, within every sink, every day.
The scale of the problem is not abstract. NHS-attributable healthcare associated infections are estimated to cost the NHS £2.7 billion a year in England alone, contributing to roughly 28,500 patient deaths and over 7 million lost bed days, according to peer-reviewed analysis published in BMJ Open.
Globally, antimicrobial resistance already directly accounts for more than a million deaths a year, and that figure is projected to climb toward 10 million annually by 2050. Between now and 2050, the toll is expected to exceed 39 million lives. This is not a future problem. It is happening now and is why Mueller Europe Healthcare & Life Sciences was established.
This is where AseptiFlow changes the equation.
Invented by Dr James Soothill MBBS, MD, FRCPath, a Consultant Microbiologist at Great Ormond Street Hospital, AseptiFlow is a passive mechanical device fitted to the drain outlet, sitting below the plug and above the U-Bend and iss engineered to prevent “splash-back” and aerosol transmission from ascending back into the clinical environment. There is no power requirement, no consumables, no maintenance contracts are required and most importantly, there is no impact to staff behaviour or working practices.
A randomised controlled trial published in the Journal of Hospital Infection in 2025 demonstrated a statistically significant reduction in contamination, giving estates and IPC teams something rare in this space, hard clinical evidence verifying a readily available product which directly aids in the fight against transmission risks associated with multidrug-resistant gram-negative bacteria.
Manufactured from the highest grade copper by Mueller Europe, AseptiFlow™ also carries copper’s inherent antimicrobial properties as a secondary benefit, on top of its primary mechanical function. This was one key reason why Great Ormond Street identified Mueller Europe as the perfect partner to manufacture and commercialise their invention, as the antimicrobial benefits of copper added an extra layer of defence into AseptiFlow.
For NHS Trusts, hospices, care homes, and any setting managing the risk of multidrug-resistant infections, or sites exposed to such infections, including hotels and leisure facilities, the case for action is straightforward. The transmission route is already documented and the solution to prevent the ascending of wastewater back into clinical environments now exists.
The only question is whether it gets addressed before or after the next outbreak, as Paul Owen from Mueller Europe Healthcare & Life Sciences was quoted as saying “AseptiFlow is a key tool to help fight antimicrobial resistance and nosocomial infections. Patient and people safety must be engineered into the built environment, not managed after failure. The cost of doing nothing, far outweighs the cost of doing something now.”
Specify AseptiFlow™. Close the pathway. Protect the places that heal.
For more information on how Mueller Europe Healthcare & Life Sciences can help you in your fight against multidrug-resistant gram-negative bacteria, please contact:
Paul Owen
Global Business Unit Manager, Healthcare & Life Sciences, Mueller Europe
Email: powen@muellereurope.com
Tel: 07467 707 838
LinkedIn: www.linkedin.com/in/paulowen-mueller





























